Vicore Pharma Holding AB（VCRE）股票分析

AI 分析 of Vicore Pharma Holding AB (VCRE)

買進

Vicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.

估值指標

Vicore Pharma Holding AB（VCRE）目前預期本益比為 0.00，5 年平均預期本益比為。

預期本益比

5 年均值 P/E

目前P/E

0.00

預期 EV/EBITDA

5 年均值 EV/EBITDA

目前EV/EBITDA

0.00

預期股價營收比

合理

5 年均值 P/S

13.42

目前P/S

5.78

高估

36.44

低估

-9.61

VCRE 常見問題 —— 由 Alphio AI 解答

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB. It operates in the Healthcare sector.

Vicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.